Xoma Corp. (NASDAQ:XOMA) released its quarterly earnings data on Wednesday. The company reported ($2.08) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($2.40) by $0.32. The company earned $0.64 million during the quarter, compared to analysts’ expectations of $1.29 million. The company’s quarterly revenue was down 69.1% compared to the same quarter last year.

Xoma Corp. (NASDAQ:XOMA) opened at 5.65 on Friday. The stock has a 50 day moving average price of $2.96 and a 200 day moving average price of $1.22. Xoma Corp. has a 12-month low of $0.34 and a 12-month high of $7.33. The stock has a market cap of $34.06 million, a P/E ratio of 25.00 and a beta of 3.71.

Earnings History for Xoma Corp. (NASDAQ:XOMA)

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its position in Xoma Corp. by 19.6% in the second quarter. Vanguard Group Inc. now owns 5,321,901 shares of the company’s stock valued at $2,934,000 after buying an additional 871,594 shares during the period. Spark Investment Management LLC increased its position in Xoma Corp. by 100.9% in the second quarter. Spark Investment Management LLC now owns 203,900 shares of the company’s stock valued at $112,000 after buying an additional 102,400 shares during the period. Finally, Paloma Partners Management Co bought a new position in Xoma Corp. during the second quarter valued at approximately $185,000.

Several research analysts have recently commented on the company. Wedbush reiterated an “outperform” rating and issued a $17.00 price objective on shares of Xoma Corp. in a report on Wednesday, October 19th. Cowen and Company reiterated a “market perform” rating on shares of Xoma Corp. in a report on Thursday. Zacks Investment Research upgraded Xoma Corp. from a “hold” rating to a “buy” rating and set a $6.00 price objective on the stock in a report on Wednesday, October 26th. Finally, Jefferies Group reiterated a “hold” rating on shares of Xoma Corp. in a report on Friday, August 5th. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $8.33.

About Xoma Corp.

XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab.

5 Day Chart for NASDAQ:XOMA

Receive News & Stock Ratings for Xoma Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xoma Corp. and related stocks with our FREE daily email newsletter.